There is a lot of disagreement, even within the neuroendocrine tumor (NET) circles, that there are biomarkers that predict outcomes and some that may even predict responses to therapy, explained ...
The new website introduces a personalised patient hub experience aimed at helping people navigate every stage of the NET ...
MIAMI, FLORIDA (April 30, 2024) – Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine ...
T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited to the pancreas and size 2–4 cm T3 Tumor limited to the pancreas and size >4 cm or invading duodenum or bile duct T4 Tumor invading ...
Symptoms of neuroendocrine tumors (NETs) can vary depending on their location and severity. General symptoms include extreme fatigue, unexplained weight loss, and loss of appetite. NETs are a rare ...
The main market opportunities in DLL3-targeted immunotherapies lie in the treatment of high unmet needs in small cell lung cancer and neuroendocrine carcinomas. The surge in research highlights ...
Medical researchers found a way to grow samples of different types of neuroendocrine tumors (NETs) in the lab. While generating their new model, the researchers discovered that some pulmonary NETs ...
Neuroendocrine cells are unique in their ability to act both as nerve cells and hormone-making cells. They're scattered throughout the body, including the stomach, intestines, pancreas and lungs.
Cabozantinib improves progression-free survival (PFS) in patients with advanced extrapancreatic neuroendocrine tumors and pancreatic neuroendocrine tumors compared with placebo. Cabozantinib, an oral ...
Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results